APP: Amyloid-beta precursor protein
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis.
- Drugs that act on it: 13
- Approved: 3
- In phases 1 to 3: 10
- Sponsors: 9
Who Is On It, and How Far Along
Every drug ChEMBL records acting on APP, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
- Antibody
- Protein or peptide
- Other
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule215%
- Antibody862%
- Protein or peptide215%
- Other18%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Lecanemab | Approved | Eisai | Antibody | Inhibitor | Amyloid-beta A4 protein inhibitor | 30 | Boxed warning |
| Donanemab | Approved | Eli Lilly | Antibody | Disrupting agent | Amyloid-beta A4 protein disrupting agent | 15 | — |
| Aducanumab | Approved | Biogen | Antibody | Binding agent | Amyloid-beta A4 protein binding agent | 1 | Boxed warning |
| Gantenerumab | Phase 3 | Roche | Antibody | Binding agent | Amyloid-beta A4 protein binding agent | 1 | — |
| Solanezumab | Phase 3 | Eli Lilly | Antibody | Binding agent | Amyloid-beta A4 protein binding agent | 1 | — |
| Bapineuzumab | Phase 3 | Pfizer | Antibody | Binding agent | Amyloid-beta A4 protein binding agent | 0 | — |
| Crenezumab | Phase 3 | Roche | Antibody | Inhibitor | Amyloid-beta A4 protein inhibitor | 0 | — |
| Tramiprosate | Phase 3 | Bellus Health Inc. - a GSK company | Small molecule | Stabiliser | Amyloid-beta A4 protein stabiliser | 0 | — |
| Valiltramiprosate | Phase 3 | Alzheon Inc. | Small molecule | Stabiliser | Amyloid-beta A4 protein stabiliser | 0 | — |
| Amilomotide | Phase 2 | Novartis Pharmaceuticals | Protein or peptide | Vaccine antigen | Amyloid-beta A4 protein vaccine antigen | 0 | — |
| GSK933776 | Phase 2 | GSK | Other | Binding agent | Amyloid-beta A4 protein binding agent | 0 | — |
| Ponezumab | Phase 2 | Pfizer | Antibody | Binding agent | Amyloid-beta A4 protein binding agent | 0 | — |
| Vanutide cridificar | Phase 2 | Pfizer | Protein or peptide | Vaccine antigen | Amyloid-beta A4 protein vaccine antigen | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Alzheimer disease
- 0.81
- Alzheimer disease type 1
- 0.79
- Cerebral amyloid angiopathy, APP-related
- 0.75
- Dementia
- 0.70
- Hereditary cerebral hemorrhage with amyloidosis
- 0.63
- ABeta amyloidosis, dutch type
- 0.50
- ABeta amyloidosis, Italian type
- 0.50
- ABeta amyloidosis, Iowa type
- 0.50
- ABeta amyloidosis, Arctic type
- 0.50
- ABetaA21G amyloidosis
- 0.50
- ABetaL34V amyloidosis
- 0.47
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2487, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P05067, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets